BRIGHT and LanzaTech launch new partnership to accelerate carbon-to-value biotechnology in Europe
Rhea-AI Summary
BRIGHT (DTU) and LanzaTech (NASDAQ: LNZA) signed a multi-year partnership through April 2028 to design and install a next-generation C1 biofoundry at DTU. The collaboration provides a non-exclusive license to LanzaTech biofoundry workflows and aims to accelerate gas-fermentation R&D converting CO, CO₂ and methane into fuels, chemicals and materials.
The biofoundry will combine automation, AI, robotics and specialized gas-handling for high-throughput strain development, enabling faster Design–Build–Test–Learn cycles and shared research access across Denmark and Europe.
AI-generated analysis. Not financial advice.
Positive
- Multi-year partnership in place through April 2028
- Next-generation C1 biofoundry to be designed and installed at DTU
- Non-exclusive IP license and tailored workflows from LanzaTech
- High-throughput strain development using automation, AI and gas-handling
Negative
- None.
News Market Reaction – LNZA
On the day this news was published, LNZA declined 0.58%, reflecting a mild negative market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $1M from the company's valuation, bringing the market cap to $242.34M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Sector peers showed mixed moves: DXST appeared in momentum scanners up 8.72%, while PESI was down 14.27%. With LNZA down 2.87% pre-news and no consistent peer direction, trading appears more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 31 | Earnings and financing | Negative | -8.6% | FY 2025 results with improved loss but added private placement and grants. |
| Jan 28 | Project announcement | Positive | +0.4% | Announcement of DRAGON II SAF and renewable diesel project in the UK. |
| Jan 27 | Project contract win | Positive | -7.4% | Contract to build next‑generation ethanol facility in India under SED initiative. |
| Jan 22 | Private placement | Negative | -3.1% | Closing of $20M common stock private placement and grant updates. |
| Jan 07 | Operational milestone | Positive | -2.8% | Japan MSW-to-ethanol pilot exceeding guaranteed performance metrics over 14 days. |
LNZA often saw negative or modest reactions even to operationally positive updates, while financing and earnings news also tended to pressure shares.
Over the last six months, LanzaTech reported FY 2025 results with improved net loss and a private placement on Mar 31, 2026, which was followed by a -8.56% move. Earlier, positive project and contract wins in the UK SAF project (Jan 28, +0.42%) and India ethanol facility (Jan 27, -7.38%) showed mixed price reactions. Financing-related updates such as the $20M private placement on Jan 22 led to a -3.10% move. Even strong technical success at the Japan MSW-to-ethanol plant on Jan 7 coincided with a -2.80% reaction, indicating a pattern of cautious sentiment around the stock.
Market Pulse Summary
This announcement highlights a multi-year BRIGHT partnership that deepens LanzaTech’s C1 biofoundry footprint in Europe and supports carbon-to-value biotechnology. It complements earlier project wins and technical milestones, reinforcing the company’s gas‑fermentation platform. At the same time, recent filings and earnings have underscored financing needs and execution challenges, so investors may watch how this collaboration translates into tangible projects, commercial agreements, and follow‑on funding over time.
Key Terms
gas fermentation technical
synthetic biology technical
ai-driven design tools technical
design–build–test–learn loop technical
anaerobic technical
AI-generated analysis. Not financial advice.
A multi-year collaboration will establish a next-generation C1 biofoundry at DTU to convert industrial carbon emissions into fuels, chemicals, and materials
COPENHAGEN, Denmark, May 06, 2026 (GLOBE NEWSWIRE) -- BRIGHT, the Novo Nordisk Foundation Biotechnology Research Institute for the Green Transition at the Technical University of Denmark (DTU) and LanzaTech Global, Inc. (NASDAQ: LNZA) (“LanzaTech”), a global leader in gas fermentation, have entered a multi-year agreement to accelerate development of technologies that convert carbon emissions into valuable products.
The partnership runs until April 2028 and includes the design and installation of a next-generation C1 biofoundry at DTU. This allows LanzaTech to extend its world-class synthetic biology expertise, leveraging BRIGHT’s infrastructure, talent, and regional reach. At the same time, DTU will gain the tools and expertise needed to establish Denmark and Europe as an important player in the emerging field of carbon-to-value biotechnology, accelerating innovation in the field of circular and competitive bioeconomy.
“DTU has a history of driving innovation from the lab to commercial deployment. Our new partnership with LanzaTech emphasizes our commitment to accelerate bio-solutions innovation for the benefit of Denmark, Europe and beyond,” says DTU provost, Christine Nellemann.
From carbon emissions to sustainable products
The new biofoundry will utilize gas fermentation where microbes transform CO₂, CO and methane into fuels, chemicals and materials. The technology is emerging as a key pathway for reducing industrial emissions and enabling circular, climate-positive solutions. Engineering these specialized microbes is, however, difficult, requiring advanced automation, AI, robotics, gas-handling and high-throughput strain-development tools.
“This partnership brings unique capabilities to Denmark and accelerates our ambition to turn carbon emissions into valuable products. Working with LanzaTech strengthens our ability to drive sustainable innovation with real impact,” says Luuk van der Wielen, Director of BRIGHT.
LanzaTech has spent more than 15 years developing world-leading synthetic biology capabilities for carbon-fixing, gas-fermenting organisms, including the first dedicated biofoundry for these challenging microbes. LanzaTech’s unique biofoundry solution is purpose built for non-model organisms with highly customized anaerobic and gas handling capabilities and advanced workflows validated through many years of operation.
“We are delighted to partner with BRIGHT, whose vision, expertise, and commitment to transformative research make them the ideal partner for LanzaTech. This marks a significant milestone in our transformation. By creating a dedicated team that consolidates our biotechnology know-how, we can focus the broader team on our commitment to delivering commercial sustainable aviation fuel and biorefining projects,” says LanzaTech CEO, Jennifer Holmgren.
Under the new agreement, a LanzaTech team will develop tailored methods and workflows for BRIGHT’s research missions, provide a non-exclusive license to relevant IP for tools and biofoundry workflows, and design and install a customized C1 biofoundry at DTU.
FACTS
Why this partnership matters
Recent advances in C1 biofoundry design at LanzaTech have created new opportunities to develop production strains more efficiently, enabling conversion of CO, CO₂ and methane off-gases into valuable fuels, chemicals and materials. Access to these capabilities is currently limited, slowing research and technology development worldwide.
Establishing a next-generation C1 biofoundry at BRIGHT will close this gap and create a shared platform for researchers, partners and innovation activities in Denmark and across Europe.
A C1 biofoundry specialized in microbes that utilize C1 gases will enable:
- Faster strain development cycles
Automation and parallelization allow thousands of microbial designs to be generated and tested at once. - Reduced innovation risk
High-throughput workflows enable testing many more variants, helping teams fail faster and optimize sooner. - Integration of AI-driven design tools
Data from large-scale strain screening feeds into models that guide the next design cycle, accelerating the Design–Build–Test–Learn loop. - Safe, high-precision research on challenging organisms
Working with non-model, often anaerobic microbes — and with flammable or toxic gases — requires specialized equipment and know-how.
About BRIGHT
BRIGHT is a research center at the Technical University of Denmark (DTU) focused on enabling transformative research and innovation for a circular and competitive bioeconomy. Through cutting-edge science, leading research infrastructure, interdisciplinary collaboration and strong industry partnerships, BRIGHT develops next-generation biological solutions for foods, materials and chemicals.
About LanzaTech
LanzaTech (NASDAQ: LNZA) is a leader in carbon management, using its proprietary gas-fermentation platform to transform waste carbon into valuable products. Through global partnerships, LanzaTech enables the production of feedstocks for high-value markets including SAF and chemicals. Headquartered in the U.S., the company provides technology and commercial pathways that strengthen industrial resilience and unlock new economic value from carbon.
Contact: BRIGHT Luuk van der Wielen, Director of BRIGHT. Mail: luuk@dtu.dk Jochen Förster, Director of BRIGHT Biofoundry. Mail: jfor@dtu.dk https://bright.dtu.dk/ LanzaTech Freya Burton, Chief Sustainability Officer, LanzaTech. Mail: freya.burton@lanzatech.com Michael Köpke, Chief Innovation Officer of LanzaTech. Mail: Michael.koepke@lanzatech.com https://lanzatech.com/